Steady-State Pattern Electroretinography in Eyes with Glaucoma and High Myopia.
optical coherence tomography
pattern electroretinogram
retinal nerve fibre layer
visual field mean deviation
Journal
Clinical ophthalmology (Auckland, N.Z.)
ISSN: 1177-5467
Titre abrégé: Clin Ophthalmol
Pays: New Zealand
ID NLM: 101321512
Informations de publication
Date de publication:
2021
2021
Historique:
received:
31
08
2021
accepted:
02
11
2021
entrez:
25
11
2021
pubmed:
26
11
2021
medline:
26
11
2021
Statut:
epublish
Résumé
To investigate features of the steady-state pattern electroretinogram (ssPERG) in subjects with glaucoma (G), high myopia (HM; spherical equivalent ≤-6D) and glaucoma with high myopia (GHM). Our study included 48 participants divided into 3 groups (G, HM, and GHM) who each underwent monocular ssPERG testing with Diopsys NOVA PERG protocols. The ConStim protocol detects distinct topographic patterns of dysfunction 16° and 24° around the central macula. MagD is the amplitude of the average signal and MagD/Mag ratio indicates the consistency of the response. ssPERG indices were compared between groups and correlated with functional (ie, visual field mean deviation (VFMD)) and structural (ie, average retinal nerve fibre layer (RNFL) thickness; Cirrus optical coherence tomography) features. Participants had an average age of 59.4±7.6 years. Mean Humphrey VFMD was -14.22 ± 2.88dB, -2.62 ± 1.18dB and -12.80 ± 2.60dB for G, HM and GHM groups, respectively. Mean RNFL thickness was 63.0 ± 8.20μm, 69.5 ± 15.7μm and 60.6 ± 5.0μm for G, HM and GHM groups, respectively. For the 24° setting, no significant differences were noted for any of the parameters. For the 16° setting, MagD was lower in the GHM group compared to the HM group (0.29µV vs 0.52µV; p = 0.02). Significant differences were noted for the MagD/Mag ratio between HM and G groups (0.58 vs 0.40; p = 0.02) and between HM and GHM groups (0.58 vs 0.35; p = 0.002). There were positive correlations between both MagD 16° and MagD/Mag ratio 16° with VFMD (correlation coefficient [r]=0.37, p = 0.009; and r = 0.44, p = 0.002, respectively) and RNFL (r = 0.43, p = 0.002; and r = 0.48, p = 0.001, respectively). MagD/Mag ratio at 16° was significantly lower in glaucomatous eyes (with or without high myopia) compared to those with high myopia without glaucoma, suggesting that glaucoma has a distinct impact on MagD/Mag ratio at 16° irrespective of the presence of myopia.
Identifiants
pubmed: 34819717
doi: 10.2147/OPTH.S336903
pii: 336903
pmc: PMC8607345
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4455-4465Informations de copyright
© 2021 Lim et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Am J Ophthalmol. 2018 Apr;188:81-90
pubmed: 29421295
Invest Ophthalmol Vis Sci. 2012 Oct 17;53(11):7194-200
pubmed: 22997288
Biomed Res Int. 2015;2015:571314
pubmed: 26167489
Eye Contact Lens. 2009 Sep;35(5):238-41
pubmed: 19672200
J Glaucoma. 2013 Mar;22(3):219-25
pubmed: 22071557
Eur J Ophthalmol. 2001 Jul-Sep;11 Suppl 2:S41-9
pubmed: 11592530
Ophthalmologe. 1993 Apr;90(2):128-31
pubmed: 8490292
Invest Ophthalmol Vis Sci. 2013 Feb 01;54(2):1182-91
pubmed: 23307968
JAMA. 2014 May 14;311(18):1901-11
pubmed: 24825645
Doc Ophthalmol. 1997-1998;94(3):253-63
pubmed: 9682994
Br J Ophthalmol. 2002 Feb;86(2):238-42
pubmed: 11815354
J Glaucoma. 2009 Sep;18(7):535-42
pubmed: 19745668
Invest Ophthalmol Vis Sci. 2006 Nov;47(11):4881-7
pubmed: 17065502
Doc Ophthalmol. 2013 Feb;126(1):1-7
pubmed: 23073702
Clin Ophthalmol. 2019 Jul 24;13:1315-1322
pubmed: 31440021
Invest Ophthalmol Vis Sci. 2013 Mar 28;54(3):2346-52
pubmed: 23412088
Clin Ophthalmol. 2017 Jan 23;11:209-218
pubmed: 28176965
Lancet. 2011 Apr 16;377(9774):1367-77
pubmed: 21453963
Invest Ophthalmol Vis Sci. 2013 Jul 01;54(7):4422-9
pubmed: 23722389
Transl Vis Sci Technol. 2018 Sep 13;7(5):6
pubmed: 30221072
Optom Vis Sci. 2008 Jun;85(6):386-95
pubmed: 18521020
Invest Ophthalmol Vis Sci. 2011 Mar 14;52(3):1412-21
pubmed: 21087959
Curr Opin Ophthalmol. 2016 Mar;27(2):118-24
pubmed: 26720775
Ophthalmology. 2007 Feb;114(2):216-20
pubmed: 17123613
Ophthalmology. 1999 Oct;106(10):2010-5
pubmed: 10519600
Invest Ophthalmol Vis Sci. 2011 Jun 16;52(7):4300-6
pubmed: 21372021
Clin Ophthalmol. 2021 Jun 29;15:2815-2821
pubmed: 34234404
Ophthalmology. 2016 May;123(5):1036-42
pubmed: 26875007
Doc Ophthalmol. 2020 Oct;141(2):149-156
pubmed: 32152920
Curr Opin Ophthalmol. 2019 Mar;30(2):89-96
pubmed: 30562243
J Glaucoma. 2011 Apr-May;20(4):252-9
pubmed: 20520570
Ophthalmology. 2016 Jan;123(1):92-101
pubmed: 26260281
Ophthalmology. 2005 Jan;112(1):10-9
pubmed: 15629814
Invest Ophthalmol Vis Sci. 1985 Dec;26(12):1750-8
pubmed: 4066211
Lancet. 2004 May 22;363(9422):1711-20
pubmed: 15158634
JAMA Ophthalmol. 2018 May 1;136(5):507-513
pubmed: 29621390
J Ophthalmic Vis Res. 2013 Jul;8(3):199-206
pubmed: 24349662
J Glaucoma. 2014 Oct-Nov;23(8):494-500
pubmed: 23429613
Am J Ophthalmol. 2006 Jan;141(1):24-30
pubmed: 16386972